Head-to-head · WeighScore
Goldspan Health vs REMEVi
The verdict
REMEVi takes it — 73.5/100 to 68.2/100.
REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Goldspan Health | REMEVi |
|---|---|---|
| WeighScore | 68.2/100 | 73.5/100 |
| Grade | C | C |
| Scorecard rank | #161 | #75 |
| Semaglutide | $229 per 28 days (a single plan; thirteen charges a year) | $219/mo |
| Tirzepatide | $299 per 28 days (a single plan; thirteen charges a year) | $319/mo |
| Coverage | All 50 states plus Washington, D.C. | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
Graded #161 · C
Strengths
- One plan per molecule with no tier ladder to read, which removes the commonest source of a misquoted price
- Sublingual full-dose and microdose lines sit alongside the injections for readers who will not inject
- States its compounding class — dispensed by a pharmacy licensed under 503A or 503B — rather than leaving it unsaid
- Names a medical director and two clinical advisors by name and specialty
- A lab panel is genuinely required at 60 to 90 days and annually after that, which is stronger monitoring than most of this ranking asks for
Where it loses points
- The required lab panel is described as available at a low cost and its cost is stated nowhere on the site
- The hero says “/month”, the plan card says billed every 28 days and the order timeline says every four weeks — thirteen charges a year, not twelve
- “Pause, delay, or cancel at any time” on the storefront sits against a refund policy reading “all sales are final” and platform terms saying an order cannot be canceled once placed
- The tirzepatide sublingual microdose page lists compounded sublingual semaglutide microdose in its own inclusion list
- Clinicians are attributed to a partner platform while the storefront states it is not a medical practice
- No pharmacy is named, and Goldspan publishes no legal entity, address or governing law of its own
- Full-dose sublingual products exist on the catalog and are not linked from the site's own weight-loss page
Graded #75 · C
Strengths
- A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
- Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
- A daily oral semaglutide tablet is offered alongside the injection
- Available in all 50 states and DC, with no minimum commitment and no cancellation fee
Where it loses points
- The flat rate is the highest entry price of the top-scoring programs here; the cheaper $149 figure needs a full year
- No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 536 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.